Affymetrix Given Consensus Recommendation of “Hold” by Brokerages (NASDAQ:AFFX)
Shares of Affymetrix (NASDAQ:AFFX) have earned an average rating of “Hold” from the eight ratings firms that are covering the company, Analyst Ratings Network reports. Three research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $8.67.
A number of analysts have recently weighed in on AFFX shares. Analysts at Leerink Swann raised their price target on shares of Affymetrix from $7.50 to $9.00 in a research note on Friday. Analysts at Zacks reiterated an “outperform” rating on shares of Affymetrix in a research note on Thursday, June 12th. They now have a $10.00 price target on the stock.
Affymetrix (NASDAQ:AFFX) traded down 0.24% during mid-day trading on Monday, hitting $8.37. The stock had a trading volume of 135,355 shares. Affymetrix has a one year low of $4.41 and a one year high of $9.80. The stock’s 50-day moving average is $8.8 and its 200-day moving average is $8.07. The company’s market cap is $610.5 million.
Affymetrix (NASDAQ:AFFX) last announced its earnings results on Thursday, July 31st. The company reported $0.07 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.03 by $0.04. The company had revenue of $85.40 million for the quarter, compared to the consensus estimate of $83.30 million. During the same quarter last year, the company posted $0.04 earnings per share. Affymetrix’s revenue was up 7.4% compared to the same quarter last year. On average, analysts predict that Affymetrix will post $0.14 earnings per share for the current fiscal year.
Affymetrix, Inc (NASDAQ:AFFX) is engaged in the development, manufacture, sale and service of consumables and systems for genetic analysis in the life sciences and clinical healthcare markets.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.